Exact Sciences

Phase A — Understand the business

Lens 1 · Company Overview

Exact Sciences is the U.S. leader in non-invasive cancer screening and precision-oncology diagnostics, built on two franchises: Cologuard (a stool-DNA colorectal-cancer screen) and Oncotype DX (a tumor-tissue gene-expression assay that tells early breast-cancer patients whether chemo will help). In 2025 it delivered 5.5M+ patient results across its portfolio.

The revenue model is a laboratory-service model, not a product-sale model — and its single most important accounting feature is that "the Company's customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient". Revenue is recognized when an approved test result is released to the ordering provider, at a variable-consideration transaction price — the probability-weighted amount Exact expects to actually collect from a fragmented payer stack (Medicare, Medicaid, commercial, patient self-pay) after denials, co-pays, and secondary payers. A 1% change in that estimate would move ~$32.5M of revenue. This is the crux of the whole P&L: Exact does not sell a widget at a list price; it books an estimate of collections and trues it up.

• Products (screening): Cologuard (FDA 2014, the original mt-sDNA test), Cologuard Plus (FDA-approved next-gen, launched Mar 2025), Cancerguard (multi-cancer early detection / MCED blood test, launched Sept 2025 as a self-pay LDT), PreventionGenetics (germline/hereditary), Riskguard.
• Products (precision oncology): Oncotype DX Breast Recurrence Score (the flagship, 21-gene, standard-of-care), Oncotype DX Colon & DCIS, Oncodetect (molecular-residual-disease / MRD, launched Apr 2025, Medicare-covered), OncoExtra (whole-exome/-transcriptome therapy selection).
• Customers: the patient is the contractual customer; the economic customers are payers — Medicare Part B (covers Cologuard once/3yrs, ages 45–85), Medicare Advantage, commercial plans, and state Medicaid (which peg to a % of the Medicare rate).
• Key payment terms: no take-or-pay, no recurring contract — every test is a fresh collection event, which is why order-to-cash quality directly gates revenue. Cologuard is a ~3-year rescreen cycle (annuity-like at the cohort level); Oncotype is one-and-done per diagnosis.
• Suppliers / infrastructure: two owned/leased clinical labs — Madison, WI (~1.5M sq ft) and Redwood City, CA (~243k sq ft).

customers.csv, segments.csv, financials.csv in the research layer are header-only (empty) — every number in this dossier is sourced from the filings directly, not from the compiled CSVs. The _meta.json confidence is low and HQ/CEO/founded fields are blank; I've filled them from the 10-K.

Lens 2 · Supply Chain

This is a services / reagents value chain, not a hardware chain — the "supply chain" is (a) reagent and consumable inputs into the lab, (b) the lab throughput itself, and (c) the payer-collection chain that converts a released result into cash. Named stakeholders along the chain:

• Upstream IP / technology licensors (the raw material is molecular know-how): Mayo Clinic and Johns Hopkins University (foundational Cologuard/Cancerguard research), Broad Institute (MAESTRO MRD tech, licensed Jun 2023), Oxford University, Ludwig Institute, TwinStrand Biosciences (licensed 2024, $45M), and — critically — Freenome (exclusive U.S. rights to a blood-based CRC test, Aug 2025).
• The lab (the chokepoint): all U.S. testing runs through Madison, WI — a genuine single-campus dependency for Cologuard. Cologuard, Cancerguard and Oncodetect are not offered outside the U.S. at all; only Oncotype ships internationally (~120 countries, local lab in Germany since 2021).
• Sample-collection partner: Quest Diagnostics — ~7,000 patient-access/phlebotomy sites are the physical front-end for the Cancerguard blood draw. For Cologuard the "collection" is a mailed home kit, so the chokepoint there is the adherence/logistics operation, not a third party.
• Downstream demand aggregators: ordering primary-care physicians and oncologists, plus large organized screening programs / "care-gap" programs run with health systems and payers (motivated by HEDIS and Medicare Stars quality measures) — increasingly the growth channel for Cologuard.
• The collection chain: payer → billing/appeals → cash. The variable-consideration estimate is the supply-chain risk metric here.

Single-source dependency to flag: the entire domestic screening franchise runs through one Wisconsin lab campus and a Medicare/USPSTF reimbursement regime — concentration in one facility and one policy stack, not in one supplier. (Lens carried into Abbott: this is exactly the kind of integrated lab operation Abbott's core-lab diagnostics arm knows how to run and scale.)

Lens 3 · Competitive Advantages (moats)

Exact's moat is not technological uniqueness (a stool-DNA assay is replicable and blood-based rivals are arriving) — it is distribution + guideline inclusion + a payer-coverage estate that took a decade and billions of S&M to build.

1. Guideline & quality-measure lock-in (the deepest moat). Cologuard/Cologuard Plus are named in USPSTF (A grade 50–75, B grade 45–49), ACS, NCCN, NCQA/HEDIS, and Medicare Advantage Star Ratings. Because payers are measured on colorectal screening rates via HEDIS and Stars, they are structurally motivated to push a mailable test that lifts those scores. That is a demand pull competitors can't buy.
2. Reimbursement estate + the ACA no-cost-share mandate. Under ACA §2713, an "A/B"-rated USPSTF service must be covered with zero patient cost-sharing, and in June 2025 the U.S. Supreme Court (Kennedy v. Braidwood) affirmed the constitutionality of the USPSTF appointments and the mandate — directly protecting no-cost-share coverage of Cologuard. Follow-on colonoscopy after a positive Cologuard is also mandated cost-share-free. This is a legislated tailwind, now de-risked by SCOTUS.
3. Brand + DTC scale. Cologuard is a consumer brand (national TV/DTC, Cologuard.com direct ordering). ~40% of surveyed Cologuard users were previously unscreened — i.e., Exact expands the market rather than just taking share.
4. Clinical evidence depth. Cologuard Plus posted 95% cancer sensitivity / 91% specificity in the 20,000-patient BLUE-C trial (NEJM 2024), up from 92%/87% for the original — the specificity jump matters because it cuts false-positive colonoscopy referrals.
5. Oncotype DX is "the only test proven to predict both chemo benefit and recurrence" in early breast cancer, embedded in all major guidelines (TAILORx/RxPONDER evidence) — a durable standard-of-care annuity.

Bargaining power: strong over providers (they need the guideline-listed test to hit quality metrics), weaker over payers (payers set the rate; Exact must renegotiate every commercial contract, and Cologuard Plus required a fresh round of amendments after its Mar-2025 launch). Moat verdict: wide on the incumbent CRC-screening franchise, narrowing at the blood-based frontier where Guardant is credible (Lens 13).

Lens 4 · Segments

Two reported lines (screening vs precision oncology); no geographic segment breakout beyond narrative (revenue is "substantially all U.S. dollars"). All figures ``.

Screening is now 78% of revenue and rising. The mix shift is the story: the faster-growing, higher-moat franchise is becoming the whole company. Q3-2025 detail confirms the acceleration — Screening +22.3% YoY, Precision Oncology +12.7%, total +20.4% for the quarter. Screening growth is driven by "higher volume of completed Cologuard tests… increases in rescreen rates, care-gap programs, and growth in new ordering providers"; precision-oncology growth is "an increase in completed Oncotype DX breast cancer tests… particularly in Japan".

---

Phase B — Measure performance

Lens 5 · Earnings Result (FY2025 — the last clean annual print)

FY2025 is the pivotal year: revenue +17.7% to $3,247.0M while operating expenses fell as a % of revenue and operating cash flow more than doubled. The headline loss is misleading and needs unpacking. All ``, 10-k-2025-q4.md consolidated statements.

What actually happened:

• The 2024 "$1.03B loss" was almost entirely a non-cash IPR&D impairment ($830M on the Thrive/MCED asset, plus facilities) — not an operating collapse. Strip it and 2024's operating loss was ~$(180M). FY2025's $(206M) operating loss is the clean number and it shrank as a share of revenue (‑6.4% margin vs a comparable ‑6.5%).
• The real signal is cash, not GAAP EPS. Operating cash flow was $491.4M in FY2025, up $280.9M (+133%) from $210.5M. Against capex of $134.7M, that is ~$356.7M of free cash flow. Exact crossed into material positive FCF while still printing a GAAP loss — the loss is driven by $217.7M of stock-based comp + $96.7M of intangible amortization (both non-cash). Adjusted for SBC, the business is meaningfully profitable on a cash basis.
• Gross margin held at ~70% despite care-gap-program mix headwinds, on "efficiencies gained in personnel and lab automation from increased Cologuard test volume" — evidence of operating leverage in the lab.
• Cost discipline: an August-2025 multi-year productivity plan targets >$150M in annual savings by 2026 (G&A external-spend optimization, support-function restructuring, automation). G&A already fell to 27.4% of revenue (from 28.3%).
• Balance sheet (31 Dec 2025): cash & equivalents $956.0M + marketable securities $8.7M ≈ $965M liquidity; convertible notes $2.35B principal; net debt ≈ $1.39B. AR $298.7M (up +$49.7M YoY, roughly in line with revenue growth — no receivables blow-out). Inventory $166.2M (flat). Goodwill $2.37B + intangibles $920M = a heavily acquisition-built balance sheet. Total equity $2.40B; accumulated deficit $4.71B.
• Market reaction / what was priced in: irrelevant post-deal, but for the record the pre-deal tape ran hard — the stock ~doubled in the six months before the deal and rose ~130% over the prior year, closing near ~$86 before Abbott's $105 bid (a 22% premium). The market had already re-rated the FCF inflection before Abbott put a floor under it.

Latest quarterly (Q3-2025, the last 10-Q): revenue $850.7M (Screening $666.2M +22.3%, Precision Oncology $184.5M +12.7%), net loss $(19.6)M, EPS $(0.10) — a near-breakeven quarter on the way to the FCF inflection. (Note: post-close "Q1-2026" figures surfaced in web search do not reconcile with the reported segment run-rates and post-date the delisting; I do not cite them.)

Lens 6 · Earnings Calls (sentiment trend)

No transcripts/ on the shelf (transcripts=0). From filings + the deal record, management's throughline across 2024→2025 shifted from "prove we can grow profitably" to "we did — and here's the productivity plan": the recurring 2025 message was "grew revenue 18% while decreasing operating expenses as a percentage of revenue" and "generated $491.4M operating cash flow, +$280.9M". The phrases that appeared in 2025 and hadn't before: "multi-year productivity plan," ">$150M annual savings," "operating leverage." The launch cadence (Cologuard Plus, Oncodetect, Cancerguard all in 2025) signals a company that had shifted from a single-product story to a platform story. CEO Kevin Conroy publicly framed 2025 as "a transformative year". Sentiment read: confident, execution-focused, deleveraging the cost base — the exact profile that makes a strategic acquirer comfortable underwriting. `` where cited; no primary transcript on disk to sentiment-score quarter-by-quarter — a genuine gap in this dossier.

Lens 7 · Comps

The relevant comp set is liquid-biopsy / molecular-diagnostics peers. Multiples are `` with source, or n/a; I will not fabricate a multiple.

The only rigorously-sourced multiple here is the takeout itself: ~6.5–7x EV/2025-sales at $105/share. For a diagnostics asset growing high-teens with a ~70% gross margin and a decade-deep reimbursement moat, that is a full but defensible strategic price — roughly where high-quality, fast-growing dx assets change hands, and Abbott paid it precisely because the organic dx division needed the growth. 5-yr average ROE is not meaningful (persistent GAAP losses, negative-to-thin equity returns) — n/a by construction for a company that only just reached cash breakeven.

Lens 8 · Stock-Price Catalysts (5-yr, pre-delisting)

What moved EXAS >5% over its final years, and what it reveals — mostly `` / filing-dated:

• Aug 2014 — original Cologuard FDA approval (the founding catalyst; historical).
• 2020–2021 COVID — screening-volume whipsaw (elective/preventive care collapsed then rebounded); the stock traded the volume signal.
• Jan 2021 — Thrive acquisition ($2.15B) for MCED — the bet that became the $830M impairment in 2024, a repeated overhang.
• Mar 2024 — BLUE-C / Cologuard Plus NEJM data — de-risked the next-gen franchise.
• Mar 2025 — Cologuard Plus launch + Apr/Sept 2025 Oncodetect & Cancerguard launches — the "platform" re-rate.
• Jun 2025 — Kennedy v. Braidwood SCOTUS ruling — removed the ACA-mandate legal tail-risk on no-cost-share coverage.
• Aug 2025 — Freenome deal + productivity plan.
• 19 Nov 2025 — Abbott $105 bid — the terminal catalyst; stock gapped to the deal price and stopped trading on fundamentals.
• 20 Feb / 23 Mar 2026 — shareholder vote / deal close — the spread collapsed to zero and the ticker was delisted.

Pattern: the market reacted most to (1) guideline/reimbursement/regulatory events (USPSTF, ACA, SCOTUS, Medicare coverage) and (2) binary clinical/M&A events — and far less to any single quarter's revenue beat. This is a policy-and-catalyst stock, which is exactly why a strategic buyout ended the story cleanly.

---

Phase C — Judge people & books

Lens 9 · Management

• Kevin Conroy — Chairman, President & CEO since March 2014 (12-year tenure). He built Exact from a ~single-product company into a >$3B-revenue, cash-generative diagnostics platform and delivered the $21B exit at a 22% premium — a genuine franchise-builder track record. He stayed on through the transition in an advisory role post-close.
• CFO Aaron Bloomer; GM Screening Jacob Orville; GM Precision Oncology Brian Baranick; EVP HR Sarah Condella.
• Skin in the game / comp: Conroy's FY2025 total comp was ~$49.5M — salary $1.08M, stock awards $21.2M, non-equity incentive $2.02M, and ~$25.2M "all other" (elevated, consistent with change-of-control equity acceleration around the deal). Note that the golden-parachute (say-on-golden-parachute) advisory proposal FAILED at the Feb-2026 special meeting — a symbolic shareholder rebuke of the payout size — but it is non-binding and did not affect deal approval (>99% of votes cast backed the merger).
• Capital-allocation history — mixed, ultimately vindicated by the exit: the Thrive/MCED bet (Jan 2021, ~$2.15B) was impaired ~$830M in 2024 — the single worst allocation call, a classic overpay for a pre-revenue blood-based asset that ran years behind plan. Offsetting that: disciplined conversion-note laddering (2027/2028/2030/2031, ultra-low 0.375–2.0% coupons — cheap capital) and the 2025 pivot to cost discipline + FCF. He also monetized non-core IP (sold the GPS prostate test to MDxHealth). Net: an aggressive M&A/pipeline allocator who overpaid on MCED but built the core into a strategic prize — and the $105 exit is the scoreboard.
• Archetype: founder-operator/franchise-builder (long-tenured, brand-forward, R&D-heavy), not a caretaker. Implication: the value was in the distribution + reimbursement machine he built, which is precisely what Abbott bought.

Lens 10 · Forensic Red Flags

Clean, with the one structural soft-spot every diagnostics lab has. All `` unless noted.

• The single accounting risk that matters — revenue = variable consideration on receivables. PwC flagged "Valuation of Net Accounts Receivable — Variable Consideration" as the sole critical audit matter. Revenue is an estimate of collections (no patient contract), trued up over time. Management discloses that historical true-ups run ~1% of prior-year revenue and a 1% shift ≈ $32.5M — i.e., a bounded, disclosed, historically-stable estimation risk, not a manipulation flag. AR grew +$49.7M (+20%) roughly in line with the +17.7% revenue — no divergence of receivables outrunning sales.
• Cash vs earnings — cash is the stronger number. OCF $491.4M dwarfs the $(207.9)M net loss; the gap is non-cash SBC ($217.7M) + amortization ($96.7M) + the $7.2M impairment. No red flag — this is the healthy direction (cash > GAAP earnings).
• SBC is real dilution, not a flatter-the-numbers trick. SBC is $217.7M = 6.7% of revenue and shares grew from 185.6M to 190.8M — dilution is material and the loss is genuinely SBC-heavy. Exact reports GAAP losses honestly; it does not lean on a heroic "adjusted" story to claim profitability. Diluted share count in the loss years excludes the convert dilution (anti-dilutive while loss-making) — a real overhang the acquisition retires.
• Goodwill/intangibles = 56% of assets ($2.37B goodwill + $0.92B intangibles of $5.86B) — the legacy of Genomic Health/Thrive/Ashion M&A. The 2024 $830M IPR&D impairment was the market marking that acquisition spree; management bypassed the qualitative test and ran a full quantitative IPR&D impairment test in 2025 and found no further impairment, with sensitivity (±1% discount rate, ±5% cash flows) not triggering a charge — transparent handling.
• Contingent consideration & off-balance obligations (the hidden liabilities): $450M more payable to Thrive's ex-holders on FDA approval + CMS coverage of the blood MCED (est. 2030–2031; fair-valued at $289.0M); up to $700M in Freenome milestones (incl. $100M on first-line FDA approval of its CRC blood test); single-digit royalties across licensed tech. These are large, real, milestone-gated future cash calls — now Abbott's to fund.
• Going-concern / liquidity: explicitly not a going-concern risk — $965M liquid + $500M undrawn JPMorgan revolver (Jan 2025, expires Jan 2028) + ~$357M FCF. The 2025 converts ($249M) were repaid in cash at maturity in Jan 2025 — no distress.

Regulatory findings (required):

• SEC: No Litigation Releases and no AAERs naming Exact Sciences in the 2021-07-06→2026-07-06 window, verified via SEC EDGAR EFTS (LR + AAER). PwC has audited since 2020 with clean opinions on both financials and internal control (ICFR) for FY2025.
• 10-K Item 3 (Legal Proceedings): incorporated by reference to Note 14 — "From time to time we are a party to various legal proceedings arising in the ordinary course of our business," with no material specific matter carved out. No securities class action, qui tam, or DOJ/OIG subpoena disclosed as material.
• Non-SEC (web): no material FTC/DOJ/FDA enforcement action, consent decree, or fine surfaced for Exact Sciences on search. The only regulatory event of note is favorable — the Kennedy v. Braidwood SCOTUS ruling (Jun 2025) upholding the ACA/USPSTF coverage mandate. Deal-related merger litigation (routine 14A disclosure suits) is common in $20B+ take-privates but did not impede the close.
• Verdict: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-07-06.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

No independent multi-year EPS model is warranted — the security is retired at a fixed $105.00 cash and no longer trades. Building a base/bull/bear EPS path for a delisted stock would be a fabricated exercise. What is worth stating (all `` from the last actuals, framed as the standalone trajectory Abbott bought, not a price forecast):

• Revenue: off FY2025 $3,247M growing ~15–18% (Screening ~20%, Precision Oncology ~9–10% blended), standalone Exact was on track for ~$3.7–3.8B in FY2026; corroborated by third-party "~$3.2B Abbott-division contribution in 2026" framing.
• Cash: the FCF inflection ($357M FY2025) plus the >$150M productivity savings implied ~$500M+ standalone FCF in FY2026, i.e., a self-funding company — the reason it could be bought with debt.
• GAAP profitability: likely within ~1–2 years on the standalone path as revenue grew into the fixed cost base and SBC/amortization stayed roughly flat as a % of revenue — but the impairment/SBC noise makes GAAP a poor lens; cash was already there.

No forecast.ts created (per --watchlist rules and because there is no live, scoreable EPS bet — the outcome is a closed cash deal at $105, already resolved).

Lens 12 · Bull vs Bear (as of the deal — retrospective)

Bull case (what Abbott was underwriting): the U.S. CRC-screening TAM is ~$22B/yr (~110M average-risk Americans 45–85, ~$592/test Cologuard Plus, 3-yr cycle) with >40% still not up-to-date and ~55M unscreened — a decade-long secular runway. Cologuard is the guideline-and-reimbursement-blessed incumbent, accelerating (+22% in Q3-2025) on Cologuard Plus's higher sensitivity and ASP. Layer on the first real FCF ($357M), the >$150M cost program, a Japan-led Oncotype tailwind, and three 2025 launches (Cancerguard MCED, Oncodetect MRD, Cologuard Plus) — a screening-to-monitoring platform. For Abbott it plugs directly into a global diagnostics distribution machine and re-accelerates a slow division. The bull case won: the deal closed at a 22% premium.

Bear case (the risks that justified selling rather than going it alone): (1) Blood-based CRC is coming and Exact's own blood test is weak — the internal assay hit only 73% CRC sensitivity / 14% advanced-adenoma at 90% specificity, far behind stool-DNA, which is why Exact paid up to $700M for Freenome's tech (Lens 13). (2) Persistent GAAP losses + $2.35B converts + $4.71B accumulated deficit + ~$1.4B net debt — a leveraged, dilutive capital structure that caps standalone multiple expansion. (3) Reimbursement/policy dependence — the whole moat rests on USPSTF/ACA/CMS coverage; favorable now (SCOTUS 2025) but a permanent political variable. Pre-mortem (had Exact stayed independent): 18 months out, Guardant Shield and other blood tests erode the new-to-screening funnel where Cologuard's ~40% previously-unscreened advantage lived, ASP compresses as payers push cheaper blood tests, the Thrive/Freenome MCED bets miss again, and the converts weigh on a still-unprofitable P&L — a plausible path that made a certain $105 cash the rational choice. Contrarian view the market missed pre-deal: Exact's value was never the stool-DNA molecule (replicable) — it was the reimbursement estate + guideline lock-in + DTC brand, an integration asset worth more inside Abbott than as a standalone mid-cap fighting a multi-front modality war. Abbott saw it; the tape (which had EXAS languishing near $53 in June 2025 before the run-up) took longer.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the standalone bull case (moot now, but the real risk map):

• The modality shift is the structural threat. Cologuard is stool-DNA; the frontier is blood. Guardant Health's Shield is FDA-approved, got into the 2026 ACS colorectal guidelines, and boasts >90% real-world completion across ~200k patients — because a blood draw at a routine visit beats mailing a stool kit home. Shield is clinically worse at the thing that matters (83% CRC sensitivity, ~13% advanced-adenoma vs Cologuard Plus 95%/74%) — but convenience drives adherence, and adherence is where Exact's ~40%-previously-unscreened moat actually lives. If blood tests win the never-screened patient at the point of care, Cologuard's expansion story caps out.
• Exact's own blood test can't yet compete — 73%/14% internal performance forced the $700M Freenome dependency, i.e., Exact had to buy its way into the future modality. That is a tell that the incumbent tech is on the wrong side of the curve.
• Revenue concentration: ~78% screening, effectively one product (Cologuard) + one policy stack (Medicare/USPSTF) through one lab (Madison). A CMS rate cut, a USPSTF downgrade, or a lab disruption hits disproportionately.
• Capital allocation red flag: the Thrive $830M impairment is hard evidence management overpaid for a blood-based MCED dream once already — and then wrote another $700M Freenome check into the same thesis. Serial big-ticket bets on unproven blood assays.
• Valuation dependence: at ~6.5–7x sales for a loss-making name, the price required continued high-teens growth AND the FCF ramp AND no blood-test share loss. If growth slipped 20–30%, a standalone EXAS re-rates sharply lower — which is exactly the downside the $105 cash deal eliminated for holders. The single scenario that permanently impairs the standalone business: blood-based CRC screening becomes the payer-preferred front-line test and Cologuard is relegated to a shrinking rescreen niche. Plausibility: medium and rising — the strongest argument for why selling to Abbott at a premium was the right call.

Lens 14 · Management Questions (ordered by information value)

(Retrospective — these are the questions that would most have changed the standalone view; for Abbott, re-point them at the integrated diagnostics division.)

1. What is Cologuard's share of the never-previously-screened funnel, and how is it trending as blood-based CRC tests (Shield) reach the point of care?
2. What is the standalone ASP trajectory for Cologuard Plus ($592 today) under commercial-contract renegotiation, and what payer mix assumptions underpin it?
3. On the Freenome blood-CRC test: what performance (sensitivity/specificity/advanced-adenoma) is required to be competitive, and what is the realistic FDA-approval timeline before the $100M/$700M milestones trigger?
4. What is the incremental FCF conversion as revenue scales — does the ~$150M productivity plan compound, and what is the steady-state FCF margin?
5. What is the rescreen-cohort retention economics — of patients screened 3 years ago, what % return, and at what ASP?
6. How much of Screening growth is volume vs price vs care-gap-program mix, and what is the margin differential of care-gap volume?
7. What is the standalone path to GAAP profitability given ~$218M/yr SBC and ~$97M/yr amortization — and the plan to reduce SBC as a % of revenue?
8. On Cancerguard (MCED): what is the reimbursement and guideline path, and what does the SOAR registrational trial need to show to unlock CMS coverage?
9. What is the plan for the $2.35B converts (2027/2028/2030/2031) — refinance, convert, or cash-settle — and the dilution/interest implications of each?
10. What are the Thrive contingent milestones ($450M) probability-and-timing assumptions, and how do they interact with the Freenome path (are they the same MCED bet twice)?
11. What is the Oncotype DX international (Japan/Europe) growth ceiling and reimbursement durability?
12. What is the competitive response plan if a blood-based CRC test earns a USPSTF "A/B" grade with ACA no-cost-share coverage?
13. What is the Oncodetect (MRD) commercial ramp vs Natera Signatera, and the tumor-type expansion timeline?
14. What single reimbursement-policy change (CMS rate, USPSTF interval, Medicare Advantage Stars weighting) most threatens the screening P&L?
15. How replaceable is the Madison single-lab dependency, and what is the disaster-recovery/second-site plan?

---